Novel immuno-therapies to overcome the resistance of existing cancer treatments Builds on the world-leading research into tumour associated macrophages (TAMs) Robert Haigh joins as CEO
New UK fund cornerstoned by £50 million investment from the British Business Bank, through its Enterprise Capital Funds (ECF) programme Epidarex Capital III UK LP
Combines Best-in-Class Bone Repair with Intraoperative Ease-of-Use for Spine and Trauma Bone Grafting Applications Aberdeen, UK, 17 June 2020 – SIRAKOSS Ltd, a developer of
71% of pegcetacoplan-treated patients achieved LDH normalization vs. 15% of eculizumab-treated patients 73% of pegcetacoplan-treated patients achieved a clinically meaningful improvement in FACIT-fatigue score vs.
Financing round led by Novo Ventures and includes new investors Cowen Healthcare Investments and Sanofi Ventures, as well as existing investors 5AM Ventures, F-Prime Capital,
Brighton, Sussex, February 11th 2015 – ENTERPRISE THERAPEUTICS Ltd, a drug discovery company focused on new therapeutics for respiratory diseases, today announced that it has
Crestwood, KY – December 2nd 2014 – Apellis Pharmaceuticals, Inc., a leading biotechnology company applying immunotherapy to autoimmune disease, today announced that it has completed
EDINBURGH, UK, December 2, 2014 – SIRAKOSS, an innovative medical device company based in Edinburgh and Aberdeen today announced it has secured $4.8m (£3.1m) in
CRESTWOOD, KY November 20, 2014 – Apellis Pharmaceuticals Inc. Complement inhibition is the only mechanism thus far to show reductions in the growth of dry
Epidarex Capital, a leading international venture capital firm, has raised over £47.5 million to lead investments in early-stage life science and health technology companies, including